✦ LIBER ✦

Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track

✍ Scribed by Anne Bastie; Laurent Castera; Francoise Roudot-Thoraval; Daniel Dhumeaux; Jean-Michel Pawlotsky

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 55 KB
Volume: 31
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.510310248

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon alfa-2b in combination with r

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics

✍ Regino P. González-Peralta; Deirdre A. Kelly; Barbara Haber; Jean Molleston; Kar 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 3 views

Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur. We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We determined the optimal ribavirin dose in an initial coh

Lymphoblastoid interferon alfa-n1 improv

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial

✍ Geoffrey C. Farrell; Bruce R. Bacon; Robert D. Goldin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

The aim of this study was to compare the short-term and long-term efficacy and safety of lymphoblastoid interferon with a recombinant interferon alfa (IFN-␣) in a 24-week treatment course for chronic hepatitis C. One thousand seventy-one patients with chronic hepatitis C were randomized to receive l

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may